Article

Post-HSCT maintenance treatment using entrectinib for an AML patient accompanied ETV6-NTRK3: a case report

2022-11-21

Abstract excerpt

The neurotrophic receptor tyrosine kinases (NTRKs) gene fusions occur in many different tumors, and tropomyosin receptor kinase (TRK) inhibitors exhibit attractive antitumor activity. This case report presents that a patient with refractory AML accompanied ETV6-NTRK3 was failed in traditional chemotherapy, then received continue remission after hematopoietic stem cell transplantation (HSCT) and maintenance therapy...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c3caf35f-08be-53b7-9380-8358d713c16f
DOI: 10.21203/rs.3.rs-2285182/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Post-HSCT maintenance treatment using entrectinib for an AML patient accompanied ETV6-NTRK3: a case reportDOI 10.21203/rs.3.rs-2285182/v1Read

ETV6-NTRK3 is Associated With Trisomy 8 and Sensitive to TRK Inhibitor in Hematologic Malignancy: Case Report of a Refractory AML and Review of the LiteratureSemantic proximity Read

Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins.Semantic proximity Read

A review of NTRK fusions in cancerSemantic proximity Read

Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in ChinaSemantic proximity Read

Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinibSemantic proximity Read

NTRK Fusion-positive Non-small-cell Lung Cancer: The Diagnosis and Targeted Therapy.Semantic proximity Read

Prevalence of neurotrophic tropomyosin receptor kinase ( NTRK ) fusion gene positivity in patients with solid tumors in JapanSemantic proximity Read

Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion CancerSemantic proximity Read

Investigating the Natural History and Prognostic Nature of NTRK Gene Fusions in Solid TumorsSemantic proximity Read

Development of a Cell Line Containing the Chimeric ETV6-NTRK3 Gene. The Search for Mutations of the Tyrosine Kinase Chimeric Domain That Cause Resistance to Larotrectinib.Semantic proximity Read

Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidenceSemantic proximity Read

Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusionSemantic proximity Read